e-NA Biotec Inc. is a drug discovery bio-venture company originating from Gifu University. Based on the research results of professors both, Dr. Kitade and Dr. Akao at Gifu University for many years, we aims to bring microRNA medicine (nucleic acid medicine) to the market and patient.
Our company was established on January 11, 2018 under program for creating start-ups from advanced research and technology (START) supported by the National Institute of Science and Technology Agency (JST) in japan.
In the field of nucleic acid medicine, where exponential design exists, we are continuing research and development of the world's first Ras-targeted microRNA medicine using highly chemically modified microRNAs discovered by utilizing our know-how.
MicroRNAs are bio-molecules that regulate our individual gene expression in the cell. More than 2500 microRNAs have already been reported in the humans (from miRBase, as of April 2022).
It is suggested that an imbalance in the quantity of microRNAs in a cell causes cancer and other diseases.
We are focusing on microRNAs as potential therapeutic drugs, especially for unmet or intractable cancers for which there are few treatment options.
Our mission is to advance microRNA drug candidates (seeds) into preclinical and clinical trials as quickly as possible and to make therapeutics available to patients in unmet medical needs worldwide.
Through our business, we believe that we can improve the quality of life of patients and contribute to society by creating a new future based on science, based on the knowledge we have gained through our long-standing research on nucleic acids.
|Name of the Company||e-NA Biotec Inc.|
|Foundation||11th of Jan, 2018 supported by JST's START project|
|Location||#302 3-12-3, Inaba St. Gifu city, 500-8043 JAPAN|
Yukio KITADE, phD, CEO
Tsuyoshi YOKOI, phD
Hideo MARUHASHI, phD